PE20061344A1 - Forma cristalina el clorhidrato 4-ciano-n{(2r)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil}-n-piridin-2-il-benzamida - Google Patents

Forma cristalina el clorhidrato 4-ciano-n{(2r)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil}-n-piridin-2-il-benzamida

Info

Publication number
PE20061344A1
PE20061344A1 PE2006000236A PE2006000236A PE20061344A1 PE 20061344 A1 PE20061344 A1 PE 20061344A1 PE 2006000236 A PE2006000236 A PE 2006000236A PE 2006000236 A PE2006000236 A PE 2006000236A PE 20061344 A1 PE20061344 A1 PE 20061344A1
Authority
PE
Peru
Prior art keywords
crystalline form
propil
cyane
dioxin
piperazin
Prior art date
Application number
PE2006000236A
Other languages
English (en)
Inventor
Eric N C Brownec
Michel Bernatchez
Abdolsamad Tadayon
Anthony F Hadfield
Mark Lankau
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20061344A1 publication Critical patent/PE20061344A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A FORMAS CRISTALINAS Y AMORFAS DEL CLORHIDRATO 4-CIANO-N-{(2R)-2-[4-(2,3-DIHIDRO-BENZO[1,4]DIOXIN-5-IL)-PIPERAZIN-1-IL]-PROPIL}-N-PIRIDIN-2-IL-BENZAMIDA, EN DONDE LA FORMA CRISTALINA TIENE UN PATRON DE DIFRACCION DE RAYOS X EXPRESADOS EN TERMINOS DE 2* QUE COMPRENDE PICOS CARACTERISTICOS DE ALREDEDOR 14,3º; 16,14º; 16,8º; 19,0º; 21,8º; 22,3º; ENTRE OTROS Y MUESTRA UNA ENDOTERMICA MAXIMA DE ALREDEDOR DE 225 HASTA 245ºC. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA DONDE DICHA FORMA CRISTALINA ESTA PRESENTE EN AL MENOS ALREDEDOR DE 50%, EN PESO DEL TOTAL. EL COMPUESTO ES ANTAGONISTA DEL RECEPTOR DE SEROTONINA 5-HT1A SIENDO UTIL EN EL TRATAMIENTO DE ESQUIZOFRENIA, ENFERMEDAD DE PARKINSON, ANSIEDAD, ENFERMEDAD DE ALZHEIMER
PE2006000236A 2005-03-01 2006-03-01 Forma cristalina el clorhidrato 4-ciano-n{(2r)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil}-n-piridin-2-il-benzamida PE20061344A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65757505P 2005-03-01 2005-03-01

Publications (1)

Publication Number Publication Date
PE20061344A1 true PE20061344A1 (es) 2007-01-03

Family

ID=36659970

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000236A PE20061344A1 (es) 2005-03-01 2006-03-01 Forma cristalina el clorhidrato 4-ciano-n{(2r)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil}-n-piridin-2-il-benzamida

Country Status (19)

Country Link
US (2) US20070027162A1 (es)
EP (1) EP1853593A1 (es)
JP (1) JP2008531694A (es)
KR (1) KR20070112797A (es)
CN (1) CN101137648A (es)
AR (1) AR053152A1 (es)
AU (1) AU2006218845A1 (es)
BR (1) BRPI0609370A2 (es)
CA (1) CA2599588A1 (es)
CR (1) CR9319A (es)
GT (1) GT200600098A (es)
IL (1) IL185267A0 (es)
MX (1) MX2007010524A (es)
NI (1) NI200700217A (es)
NO (1) NO20074254L (es)
PE (1) PE20061344A1 (es)
RU (1) RU2007131044A (es)
TW (1) TW200700413A (es)
WO (1) WO2006093853A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080043855A (ko) * 2005-09-09 2008-05-19 와이어쓰 레코조탄을 포함하는 약학적 제형 및 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101722A (en) * 1991-05-02 1996-05-14 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5568992A (en) * 1995-05-19 1996-10-29 Caterpillar Paving Products Inc. Screed control system for an asphalt paver and method of use
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6287839B1 (en) * 1997-11-19 2001-09-11 Genencor International, Inc. Cellulase producing actinomycetes, cellulase produced therefrom and method of producing same
US6127062A (en) * 1998-03-24 2000-10-03 Duracell Inc End cap seal assembly for an electrochemical cell
EP1112270B1 (en) * 1998-09-10 2007-03-21 F. Hoffmann-La Roche Ag Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists
IT1318394B1 (it) * 2000-03-17 2003-08-25 Enichem Spa Processo per la preparazione di 1-esene.
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
US7091349B2 (en) * 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
CN1304388C (zh) * 2002-03-12 2007-03-14 惠氏公司 合成手性n－芳基哌嗪的方法
BR0308315A (pt) * 2002-03-12 2004-12-28 Wyeth Corp Preparação de ácido n1-(2'-piridil)-1,2-propanodiamina sulfâmico e seu uso na sìntese de piperazinas biologicamente ativas
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
TWI257220B (en) * 2005-03-25 2006-06-21 Ind Tech Res Inst Cross-layer rate adaptation mechanism for WLAN

Also Published As

Publication number Publication date
TW200700413A (en) 2007-01-01
WO2006093853A1 (en) 2006-09-08
US20090192311A1 (en) 2009-07-30
GT200600098A (es) 2006-11-09
CR9319A (es) 2008-01-21
IL185267A0 (en) 2008-02-09
JP2008531694A (ja) 2008-08-14
RU2007131044A (ru) 2009-04-10
CA2599588A1 (en) 2006-09-08
AR053152A1 (es) 2007-04-25
BRPI0609370A2 (pt) 2010-03-30
KR20070112797A (ko) 2007-11-27
CN101137648A (zh) 2008-03-05
NO20074254L (no) 2007-09-24
AU2006218845A1 (en) 2006-09-08
US20070027162A1 (en) 2007-02-01
MX2007010524A (es) 2008-01-16
EP1853593A1 (en) 2007-11-14
NI200700217A (es) 2008-07-24

Similar Documents

Publication Publication Date Title
CL2008003787A1 (es) Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras.
AR122395A2 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
ECSP088593A (es) 5-(arilsulfonil)-pirazolopiperidinas
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
PE20081690A1 (es) Sal de tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
AR072490A1 (es) 1,2,5- oxadiazoles como inhibidores de indolamina 2,3 dioxigenasa
PE20061319A1 (es) Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
CL2007002891A1 (es) Trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol 50% amorfo en base al peso total del compuesto; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno seleccionado entre e
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
JP2007145875A5 (es)
SV2009002858A (es) Nueva forma polimorfica y la forma amorfa de 5- cloro-n-([(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il]-metil)-2-tiofenocarboxamida
CL2008002808A1 (es) Compuestos derivados de benzoxazol, agonistas del receptor muscarinico m1; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamiento de esquizofrenia, alteraciones cognitivas o enfermedad de alzheimer.
ECSP088499A (es) Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia
WO2007039462A3 (en) Indane derivatives as mch receptor antagonists
CL2007001030A1 (es) Compuestos derivados de heterociclilguanidina; y composicion farmaceutica, util para el tratamiento de la enfermedad de alzheimer, demencia senil y demencia asociada a enfermedad de parkinson entre otras.
CL2007003289A1 (es) Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam
PE20130218A1 (es) Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
EA016687B8 (ru) Производные циклопропиламида
ECSP066866A (es) Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas
TW200735878A (en) Pharmaceutical compositions
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
BR0312169A (pt) Composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afligido por uma condição patológica ou doença suscpetivel de redução por antagonismo de receptores muscarìnicos m3 e produto de combinação
ATE413173T1 (de) Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung

Legal Events

Date Code Title Description
FC Refusal